Hans‐Henning Flechtner

21.9k total citations · 1 hit paper
117 papers, 15.2k citations indexed

About

Hans‐Henning Flechtner is a scholar working on Oncology, Pediatrics, Perinatology and Child Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hans‐Henning Flechtner has authored 117 papers receiving a total of 15.2k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Oncology, 36 papers in Pediatrics, Perinatology and Child Health and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hans‐Henning Flechtner's work include Cancer survivorship and care (38 papers), Childhood Cancer Survivors' Quality of Life (36 papers) and Family Support in Illness (18 papers). Hans‐Henning Flechtner is often cited by papers focused on Cancer survivorship and care (38 papers), Childhood Cancer Survivors' Quality of Life (36 papers) and Family Support in Illness (18 papers). Hans‐Henning Flechtner collaborates with scholars based in Germany, Belgium and Netherlands. Hans‐Henning Flechtner's co-authors include David Osoba, A. Cull, N. Duez, S. Kaasa, Bengt Bergman, Marianne Sullivan, K.C.A. Sneeuw, Stewart B. Fleishman, J.C.J.M. de Haes and M. Klee and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and JNCI Journal of the National Cancer Institute.

In The Last Decade

Hans‐Henning Flechtner

114 papers receiving 14.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

1993 11.9k citations Hans‐Henning Flechtner, David Osoba et al. JNCI Journal of the National Cancer Institute profile →

Peers

Countries citing papers authored by Hans‐Henning Flechtner

Since Specialization

Citations

This map shows the geographic impact of Hans‐Henning Flechtner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Henning Flechtner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Henning Flechtner more than expected).

Fields of papers citing papers by Hans‐Henning Flechtner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans‐Henning Flechtner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Henning Flechtner. The network helps show where Hans‐Henning Flechtner may publish in the future.

Co-authorship network of co-authors of Hans‐Henning Flechtner

This figure shows the co-authorship network connecting the top 25 collaborators of Hans‐Henning Flechtner. A scholar is included among the top collaborators of Hans‐Henning Flechtner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans‐Henning Flechtner. Hans‐Henning Flechtner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types 2023 ·European Journal of Cancer ·Jammbe Musoro, Corneel Coens, Mirjam A. G. Sprangers, Yvonne Brandberg, Mogens Grøenvold, Hans‐Henning Flechtner, Kim Cocks, Galina Velikova, Linda Dirven, Elfriede Greimel, Susanne Singer, Katarzyna Pogoda, Eva‐Maria Gamper, Samantha C. Sodergren, Alexander M.M. Eggermont, Michael Koller, Jaap C. Reijneveld, Martin Taphoorn, Madeleine King, Andrew Bottomley	64
2	Minimally important differences of EORTC QLQ-C30 scales in patients with lung cancer or malignant pleural mesothelioma – Interpretation guidance derived from two randomized EORTC trials 2022 ·Lung Cancer ·Michael Koller, Jammbe Musoro, Krzysztof A. Tomaszewski, Corneel Coens, Madeleine King, Mirjam A. G. Sprangers, Mogens Grøenvold, Kim Cocks, Galina Velikova, Hans‐Henning Flechtner, Andrew Bottomley	11
3	Reference values for the EORTC QLQ‐C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors 2021 ·European Journal Of Haematology ·Hugo Vachon, (unknown), (unknown), Madeline Pe, Corneel Coens, Francesca Martinelli, Catherine Fortpied, Hans‐Henning Flechtner, Maja V. Maraldo, Martin Hutchings, Paul Meijnders, Berthe M.P. Aleman, Pieternella J. Lugtenburg, (unknown), Marc André, Mark Hertzberg, Javier Briones, Andrew Bottomley, (unknown)	3
4	Author Correction: Hodgkin lymphoma 2021 ·Nature Reviews Disease Primers ·Joseph M. Connors, Wendy Cozen, Christian Steidl, Antonino Carbone, Richard T. Hoppe, Hans‐Henning Flechtner, Nancy L. Bartlett	1
5	Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials 2021 ·BMC Cancer ·Eva‐Maria Gamper, Jammbe Musoro, Corneel Coens, Jean‐Jacques Stelmes, Claudette Falato, Mogens Grøenvold, Galina Velikova, Kim Cocks, Hans‐Henning Flechtner, Madeleine King, Andrew Bottomley, (unknown)	17
6	Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer 2020 ·Gynecologic Oncology ·Jammbe Musoro, Corneel Coens, Elfriede Greimel, Madeleine King, Mirjam A. G. Sprangers, Andy Nordin, E.B.L. van Dorst, Mogens Grøenvold, Kim Cocks, Galina Velikova, Hans‐Henning Flechtner, Andrew Bottomley	15
7	Exploration of a novel virtual environment improves memory consolidation in ADHD 2020 ·Scientific Reports ·(unknown), (unknown), (unknown), Jana Tegelbeckers, (unknown), Elke Edelmann, Jorge R. Bergado-Acosta, Hans‐Henning Flechtner, Kerstin Krauel	16
8	The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative 2015 ·JNCI Journal of the National Cancer Institute ·Efstathios Zikos, Corneel Coens, Chantal Quinten, Divine Ediebah, Francesca Martinelli, Irina Ghislain, Madeleine King, Carolyn Gotay, Jolie Ringash, Galina Velikova, Bryce B. Reeve, Eva Greimel, Charles S. Cleeland, Hans‐Henning Flechtner, Martin Klein, Joachim Weis, J. Schmucker-Von Koch, Mirjam A. G. Sprangers, Andrew Bottomley, (unknown)	27
9	Quality of life in long-term survivors following treatment for Hodgkin's disease during childhood and adolescence in the German multicentre studies between 1978 and 2002 2014 ·Supportive Care in Cancer ·Gabriele Calaminus, W Dörffel, Katja Baust, C. Teske, Marianne Riepenhausen, Jürgen Brämswig, Hans‐Henning Flechtner, Susanne Singer, Andreas Hinz, G. Schellong	29
10	Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial 2014 ·British Journal of Cancer ·Divine Ediebah, Corneel Coens, Efstathios Zikos, Chantal Quinten, Jolie Ringash, Madeleine King, (unknown), Carolyn Gotay, Elfriede Greimel, Hans‐Henning Flechtner, Joachim Weis, Bryce B. Reeve, Egbert F. Smit, (unknown), Andrew Bottomley	74
11	A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites 2013 ·Cancer ·Chantal Quinten, Francesca Martinelli, Corneel Coens, Mirjam A. G. Sprangers, Jolie Ringash, Carolyn Gotay, Kristin Bjordal, Eva Greimel, Bryce B. Reeve, John Maringwa, Divine Ediebah, Efstathios Zikos, Madeleine King, David Osoba, Martin Klein, Hans‐Henning Flechtner, J. Schmucker-Von Koch, Joachim Weis, Andrew Bottomley	155
12	Parental palliative cancer: psychosocial adjustment and health-related quality of life in adolescents participating in a German family counselling service 2012 ·BMC Palliative Care ·Franziska Kühne, Thomas Krattenmacher, Corinna Bergelt, Johanna Ernst, Hans‐Henning Flechtner, (unknown), Wolfgang Herzog, Kai von Klitzing, Georg Romer, Birgit Möller	20
13	Effect of completion-time windows in the analysis of health-related quality of life outcomes in cancer patients 2012 ·Annals of Oncology ·Divine Ediebah, Corneel Coens, John Maringwa, Chantal Quinten, Efstathios Zikos, Jolie Ringash, Madeleine King, Carolyn Gotay, Hans‐Henning Flechtner, (unknown), Joachim Weis, Egbert F. Smit, Claus Henning Köhne, Andrew Bottomley	12
14	Development of an EORTC module for the assessment of cancer related fatigue (EORTC FAR-15): Phase III results. 2007 ·UCL Discovery (University College London) ·John R. Weis, Yan-Li Gao, Thierry Conroy, Susanne Singer, Eva Hammerlid, Bernhard Holzner, Claudia Fleissner, Fabio Efficace, Juan Ignacio Arrarás, (unknown), Hans‐Henning Flechtner, Anne Lanceley, Louise Jones	1
15	Quality of life assessment in Hodgkin’s disease: A new comprehensive approach 1998 ·Annals of Oncology ·Hans‐Henning Flechtner, Jens Ulrich Rüffer, M. Henry‐Amar, W. A. M. Mellink, M. Sieber, Christophe Fermé, Houchingue Eghbali, Andreas Josting, Volker Diehl	27
16	Guidelines for the assessment of quality of life in oncology ?implementing adequate methods and their content 1994 ·Journal of Cancer Research and Clinical Oncology ·R Schwarz, J. Bernhard, Hans‐Henning Flechtner, (unknown), (unknown)	6
17	Etoposide, Adriamycin, and Cisplatinum (EAP) Combination Chemotherapy for Advanced Gastric Cancer 1990 ·Oncology Research and Treatment ·U. Räth, Hans‐Henning Flechtner, (unknown), (unknown), C. Manegold, (unknown), (unknown), Lutz Edler, P. M. Schlag, W. Queißer	7
18	5-Fluorouracil, 4-Epidoxorubicin, and Mitomycin C (FEM) Combination Chemotherapy for Advanced Gastric Carcinoma. A Phase-II Trial by the “Chemotherapiegruppe Gastrointestinaler Tumoren (CGT)” 1987 ·Oncology Research and Treatment ·Hans‐Henning Flechtner, W. Queißer, Manfred Heim, H. Henß, H. Arnold, Dieter Fritze, R. Herrmann, Holger Fritsch, (unknown), (unknown), (unknown), Lutz Edler	5
19	Chemotherapy of Advanced Gastric Carcinoma 1986 ·Oncology Research and Treatment ·W. Queißer, Hans‐Henning Flechtner	2
20	GLUCURONIDE CONJUGATION AS AN ALTERNATIVE BIOTRANSFORMATION PATHWAY OF HEXOBARBITAL AND METHOHEXITAL IN RATS WITH EXPERIMENTAL HEPATITIS AND CHOLESTASIS 1982 ·Gastroentérologie Clinique et Biologique ·E. Richter, (unknown), (unknown), (unknown), Hans‐Henning Flechtner, Reinhard Lüthen, (unknown), Nico Vermeulen, D. D. Breimer	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact